Mangosteen (Garcinia mangostana L.) a tropical fruit, has been used in traditional medicine. A frequently used part of mangosteen is the pericarp, containing a high content of xanthones. α-Mangostin, one of the major xanthone derivatives, exhibits a variety of actions, including antimicrobial, antioxidant, cytotoxic and antitumor; however, its function on the immune system is still equivocal. This study aimed to examine the immunomodulatory activities of α-mangostin on lymphocyte lineage and cytokine production in human peripheral blood mononuclear cells (PBMCs). The cytotoxic activity of α-mangostin was measured by MTT assay. The concentration of α-mangostin at 5.55 µg/mL resulted in a 50% survival of PBMCs, which was as potent a cytotoxic activity as that of paclitaxel. After 24 h of PBMCs culture, the percentages of T cells (CD3+), B cells (CD19+) and NK cells (CD3-CD16+CD56+) were not significantly changed by treatment with 1, 2 and 4 µg/mL of α-mangostin compared with untreated-PBMCs; in addition, the percentages of these lymphocytes treated with the combination of α-mangostin (1, 2 and 4 µg/mL) and the mitogen concanavalin A (ConA) was not significantly different from that of ConA-treated PBMCs. For cytokine secretion, α-mangostin (1, 2 and 4 µg/mL) did not significantly induce either proinflammatory cytokines (i.e., TNF-α and IL-1β) or cytokine of adaptive immunity (i.e., IL-2). The combination of α-mangostin (1, 2 and 4 µg/mL) and ConA did not significantly alter the relative difference of TNF-α and IL-1β compared with ConA-treated PBMCs; however, these combinations could significantly decrease the relative difference of IL-2 compared with ConAtreated PBMCs. These data indicated that α-mangostin was able to inhibit IL-2 release without interfering with human immune cells; therefore, further studies are necessary to investigate its effect on IL-2 production.
Mangosteen, Garcinia mangostana L., is a tropical tree found in Southeast Asia. It has been used in traditional medicine for the treatments of diarrhea, dysentery, infections and wounds [1, 2] . The frequently used part has been the pericarp, containing a high content of xanthones. α-Mangostin is one of the major xanthone derivatives. Numerous studies have reported a variety of its actions, such as antibacterial, antifungal, antioxidant, cytotoxic and antitumor effects both in in vitro and in vivo [3] [4] [5] . Despite the immune function playing an important role in health and the formation of diseases, studies of the actions of α-mangostin on the immune system have been limited. Therefore, the aim of this study was to investigate the immunomodulatory activities of purified α-mangostin in vitro. PBMCs were stimulated with various concentrations of α-mangostin with and without ConA. The effects of α-mangostin on lymphocyte subsets and cytokine production were determined by flow cytometric immunophenotyping and an ELISA method, respectively.
The cytotoxic activity of α-mangostin on normal human PBMCs was determined by the MTT test. After 24 h of incubation, 50% cell survival resulted from being exposed to 5.55 µg/mL of α-mangostin. For the non-cytotoxic concentration of α-mangostin, more than 95% cell viability was obtained from the concentration lower than 4.5 µg/mL ( Figure 1a) ; meanwhile, 5.85 and 2.35 µg/mL of paclitaxel (a positive control) resulted in 50% and 95% of PBMCs survival (Figure 1b ). These data indicated that α-mangostin possesses the same substantial cytotoxic property as paclitaxel.
PBMCs contain essential components of the human immune system, which mainly are lymphocytes, monocytes and a small number of NK cells [6] . To determine the immunomodulatory action of α-mangostin on immune cells (T lymphocytes, B lymphocytes and NK cells), PBMCs were cultured with α-mangostin, T-cell stimulating ConA, or a combination of the two for 24 h. The flow cytometric results showed that the percentages of CD3+ of T cells (76.0 ± 4.3, 75.5 ± 5 and 75.2 ± 3.9%) were not significantly increased by 1, 2 and 4 µg/mL of α-mangostin compared with untreated-PBMCs (72.0 ± 4.6%, P > 0.05). In combination with ConA, α-mangostin (1, 2 and 4 µg/mL) also did not significantly change the percentages of CD3+ (77.8 ± 4.7, 77.7 ± 4.3 and 77.8 ± 3.6%, respectively) compared with ConA-treated PBMCs (77.5 ± 4.9%, P > 0.05). For B cells, α-mangostin concentrations of 1, 2 and 4 µg/mL did not significantly change the percentages of CD19+ (7.6 ± 2.4, 8.2 ± 2.4 and 7.8 ± 2.3%, respectively) compared with untreated-PBMCs (8.6 ± 2.5%, P > 0.05); furthermore, the combination of α-mangostin (1, 2 and 4 µg/mL) with ConA did not affect the percentages of CD19+ (4.3 ± 1.0 , 4.7 ± 1.6, 3.8 ± 1.7 µg/mL, respectively) compared with ConA-treated PBMCs (5.5 ± 1.6%, P > 0.05). For NK cells, α-mangostin (1, 2 and 4 µg/mL) did not significantly reduce the percentages of CD16+/CD56+ (15.9 ± 3.5, 15.8 ± 4.2 and 16.3 ± 3.6%, respectively) compared with untreated-PBMCs (18.9 ± 3.4%, P > 0.05); moreover, the combination of α-mangostin (1, 2 and 4 µg/mL) with ConA did not significantly alter the percentages of NK cells (16.5 ± 4.1, 16 ± 3.8 and 15.5 ± 3.5% respectively) compared with ConA-treated PBMCs (15.4 ± 3.6%, P > 0.05) ( Figure 2 ). The results showed that α-mangostin had no significant effect on immune cells; therefore, it was suitable to develop it into a specific antitumor agent (as described by Kosem et al.) [7] , which would not interfere with the patient's immune system.
NPC Natural Product Communications
In this experiment, the effect of α-mangostin on cytokine secretion was determined by an ELISA method. TNF-α and IL-1β are proinflammatory cytokines, which play a crucial role in the pathophysiology of various diseases [8] . The role of IL-2, produced by Th cells, is to induce other cytokine syntheses and promote clonal expansion of T-, B-and NK-cells [9, 10] . To detect cytokine induction, PBMCs were treated with α-mangostin (1, 2, 4 µg/mL). The TNF-α levels (283.3 ± 423.1, 158.7 ± 199.9 and 313.3 ± 308.0 pg/mL) in the presence of α-mangostin at 1, 2 and 4 µg/mL, respectively, were not significantly higher than untreated-PBMCs (111.8 ± 92.6 pg/mL, P > 0.05) ( Figure 3a ). The IL-1β levels (132.6 ± 159.9, 98.8 ± 94.4 and 229.5 ± 125.3 pg/mL) in the presence of α-mangostin at 1, 2 and 4 µg/mL, respectively, were not significantly higher than untreated-PBMCs (81.3 ± 55.2 pg/mL, P > 0.05) (Figure 3b ). The IL-2 levels of α-mangostin-treated cells were undetectable, which were the same as for the untreated-cells (the limit of sensitivity of the ELISA kit was 7 pg/mL) ( Figure 3c ). To detect cytokine inhibition, α-mangostin was combined with ConA to treat PBMCs. ConA is a T-cell activator that subsequently induces various cytokine secretions [11, 12] . Ten µg/mL of ConA was not toxic to the cells (> 95% of cell survival) and led to the highest cytokine secretion (data not shown). The relative difference of TNF-α in the presence of a combination of ConA and α-mangostin (1, 2 and 4 µg/mL) were 95.9 ± 8.0, 102.0± 0.8 and 103.50 ± 2.7%, respectively, which were not different from the ConA-treated cells (100 ± 2.3 %, P > 0.05) (Figure 3d ). The relative difference of IL-1β levels in the presence of ConA and α-mangostin (1, 2 and 4 µg/mL) were 99.2 ± 3.5, 99.7 ± 2.1 and 99.3 ± 1.7%, respectively, which also were not different from ConA-treated cells (100 ± 0.0%, P > 0.05) (Figure 3e ). The relative difference of IL-2 levels in the presence of ConA and α-mangostin (1, 2 and 4 µg/mL) were 36.2 ± 31.0, 35.2 ± 36.7 and 33.5 ± 20.1%, respectively, which were significantly lower than ConA-treated cells (100%, P < 0.05) ( Figure 3f ). The results implied that α-mangostin did not demonstrate an inflammatory activity, which was plausibly due to its antioxidant activity, as reported by other studies [1, 4, 13] . However, α-mangostin had an inhibitory effect on IL-2 secretion, which was probably due to either directly suppressing the effect on B-cells or monocytes in PBMCs [14] or interacting with ConA to inhibit IL-2 secretion. Therefore, further studies with a large sample size are necessary to confirm the α-mangostin activities.
Experimental
Purified α-mangostin: Purified α-mangostin was kindly obtained from the Immunology Laboratory, Department of Microbiology, Mahidol University. The stock solution was prepared by dissolving 1,000 µg of α-mangostin in l mL RPMI 1640 medium supplemented with 10%, v/v, fetal calf serum (Biochrom, Berlin, Germany) and 10%, v/v, dimethyl sulfoxide (DMSO) (Labscan Asia, Bangkok, Thailand). The final DMSO concentration in each tested sample did not exceed 0.1%, v/v.
Cell viability assay:
The effect of α-mangostin on PBMCs viability was quantified using a colorimetric MTT assay. PBMCs were isolated from buffy coat obtained from healthy blood donors (Ramathibodi Hospital). The separation of blood cells was performed by density gradient centrifugation (Lymphoprep; Axis-Shield PoC, Oslo, Norway) [15] . The collected PBMCs were washed, counted, resuspended in RPMI 1640 medium and distributed into 96-well plates at 2x10 5 cells/well. Either αmangostin (final concentration, 0.5, 1, 2, 4, 6, 8 and 10 µg/mL) or paclitaxel (Boryung Pharm, Kyungki-Do, Korea; final concentration, 0.63, 1.25, 2.5, 5 and 10 µg/mL) were added to the plate and incubated for 24 h at 37ºC, 5% CO 2 and 90% humidity. MTT, 5 mg/mL (Sigma Aldrich, Vienna, Austria), was added to each well and incubated for 4 h. Detergent was added into each well to solubilize the formazan crystals by incubating overnight. The plate was read at 570 nm with a reference wavelength at 690 nm [16] . The percentage of cell survival was calculated by the following formula:
Percentage (%) of cell survival = (OD treated cells) ×100 (OD untreated cells)
PBMCs culture: PBMCs (6 x 10 6 cells/well) were seeded in the 6-well plates and treated with purified α-mangostin (final concentration 1, 2, 4 µg/mL), ConA (final concentration 10 µg/mL; Calbiochem, San Diego, CA, USA), a combination of α-mangostin and ConA (1, 2 and 4 µg/mL of α-mangostin plus 10 µg/mL of ConA), or medium alone. The plate was incubated in a 37°C, 5% CO 2 and 90% humidity incubator. After 24 h of incubation, the cells were collected to examine lymphocyte subsets and cell-free supernatants were kept at -20 ºC for cytokine detection.
Immunophenotyping:
Immunophenotyping was used to investigate the change of lymphocyte markers by α-mangostin treatment. The cultured cells in each treatment were harvested, washed 3 times and distributed in tubes (2 x 10 5 cells/tubes). The cell surface marker expression on mature human T lymphocytes (CD3+), B lymphocytes (CD19+) and NK lymphocytes (CD3-CD16+ and/or CD56+) were enumerated by staining with a 4-color immunofluorescence reagent kit (FITC-labeled CD3, PE-labeled CD16, CD56, PerCP-labeled CD45, and APC-labeled CD19; BD Biosciences, Heidelberg, Germany) for 30 min on ice. After staining, the cells were washed twice with FACS buffer and fixed in 1% paraformaldehyde in PBS. The fixed cells were kept at 4°C in the dark until the day of analysis within 5 days [17, 18] . Data acquisition was performed using a FACSCalibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA) and analyzed with FlowJo software version 10.0.5 for Microsoft (TreeStar, San Carlos, CA, USA).
Cytokine determination:
The effects of α-mangostin on immune cell-secreted cytokine (i.e., TNF-α, IL-1β and IL-2) were measured by enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, Inc., Minneapolis, MN, USA). The treated culture supernatants were thawed to room temperature and then added into the ELISA wells. The plates were processed and measured according to the manufacturer's protocol. The relative difference of each cytokine was compared with the relative difference of ConA (a positive control) within its group and was calculated by the following formula: Relative difference of cytokine (%) = (Cytokine concentration of treated PBMCs ×100)/(Cytokine concentration of ConA-treated PBMCs).
Statistical analysis:
The results were expressed as mean ± SD/SEM. For the comparison of normal distribution data, one-way ANOVA with Tukey's post hoc test or Student's t-test was applied. The nonparametric data were analyzed by the Kruskal-Wallis test with Mann-Witney U test. P-value < 0.05 was considered as statistically significant. All statistics were performed by using SPSS software (SPSS, Chicago, IL, USA).
